Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 500 Warren Corporate Center Drive WARREN NJ 07059 |
Tel: | N/A |
Website: | https://www.ptcbio.com |
IR: | See website |
Key People | ||
Matthew B. Klein President, Chief Executive Officer, Director | Pierre Gravier Chief Financial Officer | Neil Almstead Chief Technical Operations Officer |
Mark Elliott Boulding Executive Vice President, Chief Legal Officer | Christine Marie Utter Senior Vice President, Chief Accounting Officer, Head - People Services | Eric Pauwels Chief Business Officer |
Business Overview |
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA). |
Financial Overview |
For the fiscal year ended 31 December 2023, PTC Therapeutics, Inc. revenues increased 34% to $937.8M. Net loss increased 12% to $626.6M. Revenues reflect Non-US segment increase from $200.2M to $406.2M, United States segment increase of 7% to $531.7M. Higher net loss reflects Intangible asset impairment increase from $33.4M to $217.8M (expense), Amortization of intangible assets increase of 91% to $222.6M (expense). |
Employees: | 988 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $3,133M as of Dec 31, 2023 |
Annual revenue (TTM): | $937.82M as of Dec 31, 2023 |
EBITDA (TTM): | $47.69M as of Dec 31, 2023 |
Net annual income (TTM): | -$626.60M as of Dec 31, 2023 |
Free cash flow (TTM): | -$186.86M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $1,242M as of Dec 31, 2023 |
Shares outstanding: | 76,608,030 as of Feb 27, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |